Identification and Functional Implications of Sodium/<i>Myo</i>-Inositol Cotransporter 1 in Pancreatic β-Cells and Type 2 Diabetes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28202581.
- Also identified by DOI 10.2337/db16-0880.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>Myo</i>-inositol (MI), the precursor of the second messenger phosphoinositide (PI), mediates multiple cellular events. Rat islets exhibit active transport of MI, although the mechanism involved remains elusive. Here, we report, for the first time, the expression of sodium/<i>myo</i>-inositol cotransporter 1 (SMIT1) in rat islets and, specifically, β-cells. Genetic or pharmacological inhibition of SMIT1 impaired glucose-stimulated insulin secretion by INS-1E cells, probably via downregulation of PI signaling. In addition, SMIT1 expression in INS-1E cells and isolated islets was augmented by acute high-glucose exposure and reduced in chronic hyperglycemia conditions. In corroboration, chronic MI treatment improved the disease phenotypes of diabetic rats and islets. On the basis of our results, we postulate that the MI transporter SMIT1 is required to maintain a stable PI pool in β-cells in order that PI remains available despite its rapid turnover.
Medical subject headings
- Blood Glucose
- Diabetes Mellitus, Type 2
- Inositol
- Insulin
- Insulin-Secreting Cells
- Phosphatidylinositols
- Symporters